PIK3CA Gene

Overview

The PIK3CA gene encodes the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, located on chromosome 3q26.3. This gene is a critical component of the PI3K/AKT/mTOR signaling pathway, which regulates cell growth, proliferation, angiogenesis, and survival.

PIK3CA is one of the most commonly mutated oncogenes. It is highly prevalent in hormone receptor-positive (HR+)/HER2-negative advanced breast cancer and is also frequently altered in cervical squamous cell carcinoma, colorectal cancer, gastric cancer, glioma, lung cancer, and endometrial cancer. Mutations occur most often in the helical and kinase domains, with hotspot variants including E542K, E545K, and H1047R.

These mutations cause overactivation of PI3K, contributing to uncontrolled cell division, abnormal tissue growth, and cancer progression. Detection of PIK3CA mutations is essential for diagnosis, prognosis, and targeted therapy, including the use of alpelisib (PIQRAY®) in combination with fulvestrant for HR+/HER2- breast cancer.

Symptoms

While a gene mutation itself does not directly cause symptoms, cancers associated with PIK3CA mutations present with clinical manifestations depending on the organ involved:

1. Breast cancer (HR+/HER2-): Breast lumps, nipple discharge, skin dimpling, and local pain.
2. Cervical squamous cell carcinoma: Irregular bleeding, pelvic pain, or abnormal discharge.
3. Colorectal and gastric cancers: Changes in bowel habits, abdominal pain, rectal bleeding, or weight loss.
4. Glioma: Headaches, seizures, cognitive or neurological deficits.
5. Lung cancer: Persistent cough, chest pain, shortness of breath, or hemoptysis.
6. Endometrial cancer: Abnormal uterine bleeding or pelvic discomfort.

In addition, rare overgrowth syndromes like MCAP and PROS caused by PIK3CA mutations may show abnormal tissue and organ development.

Causes

The primary cause of PIK3CA mutation-related disorders is the somatic mutation of the PIK3CA gene, leading to an overactive PI3K/AKT/mTOR pathway. Key causes include:

1. Somatic Mutations in Cancer:
   1. Occur in hotspots such as E542K, E545K, and H1047R.
   2. Lead to enhanced cell signaling, uncontrolled growth, and malignancy.
2. Oncogenic Transformation:
   1. Mutant PIK3CA drives tumorigenesis in breast, colorectal, gastric, cervical, lung, and brain cancers.
3. Overgrowth Syndromes:
   1. In conditions like MCAP and PROS, PIK3CA mutations disrupt normal tissue growth patterns.

Thus, PIK3CA mutation status serves as both a driver of oncogenesis and a biomarker for disease progression.

Risk Factors

Certain populations are at higher risk of PIK3CA-related disorders:

1. Cancer Patients:
   1. Individuals with HR+/HER2 breast cancer and cervical squamous cell carcinoma show a higher prevalence.
2. Advanced Age:
   1. PIK3CA mutations are more frequently associated with older age at presentation.
3. Genetic Predisposition in Tumors:
   1. Cancers with a strong association to PI3K pathway dysregulation (breast, colorectal, gastric, endometrial, and lung).
4. Multiple Variants:
   1. Patients harboring two or three PIK3CA variants have a significantly worse prognosis compared to those with wild-type or single variants.
5. Overgrowth Disorders:
   1. Children or adults with congenital tissue overgrowth syndromes linked to PIK3CA mutations.

By identifying these risk groups, clinicians can prioritize genetic testing and personalized therapy.

Prevention

While PIK3CA mutations themselves cannot be prevented, strategies exist to reduce disease progression and improve outcomes:

1. Early Detection and Testing:
   1. Use of FDA-approved tests like QIAGEN therascreen® PIK3CA RGQ PCR Kit for comprehensive genomic profiling (CGP)through FoundationOne CDx and FoundationOne Liquid CDx.
   2. Liquid biopsy for circulating tumor DNA (ctDNA) to monitor mutation status.
2. Targeted Therapy:
   1. Use of alpelisib (PIQRAY®) with fulvestrant in HR+/HER2- breast cancer patients with confirmed PIK3CA mutations.
3. Sample Handling and Transport:
   1. Collect blood in EDTA tubes (minimum 6 mL), process plasma early, and transport within 8 hours at ambient temperature.
   2. Ensure bone marrow samples and pathology forms accompany the specimen.
4. Regular Monitoring:
   1. Patients with PIK3CA mutations should be closely followed for treatment response and disease progression.
5. Lifestyle and Supportive Care:
   1. Although not gene-specific, maintaining a healthy lifestyle, cancer screening, and adherence to therapy improve prognosis.